- Home
- OKYO vs TLPH Comparison
OKYO vs TLPH Comparison
Compare OKYO & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- TLPH
- Stock Information
- Founded
- OKYO 2007
- TLPH 2005
- Country
- OKYO United Kingdom
- TLPH United States
- Employees
- OKYO N/A
- TLPH N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- TLPH Health Care
- Exchange
- OKYO Nasdaq
- TLPH Nasdaq
- Market Cap
- OKYO 79.7M
- TLPH 64.7M
- IPO Year
- OKYO 2022
- TLPH 2011
- Fundamental
- Price
- OKYO $1.99
- TLPH $1.33
- Analyst Decision
- OKYO Strong Buy
- TLPH Strong Buy
- Analyst Count
- OKYO 1
- TLPH 1
- Target Price
- OKYO $7.00
- TLPH $6.00
- AVG Volume (30 Days)
- OKYO 118.6K
- TLPH 337.5K
- Earning Date
- OKYO 07-18-2025
- TLPH 11-12-2025
- Dividend Yield
- OKYO N/A
- TLPH N/A
- EPS Growth
- OKYO N/A
- TLPH N/A
- EPS
- OKYO N/A
- TLPH N/A
- Revenue
- OKYO N/A
- TLPH $28,000.00
- Revenue This Year
- OKYO N/A
- TLPH N/A
- Revenue Next Year
- OKYO N/A
- TLPH $14,533.26
- P/E Ratio
- OKYO N/A
- TLPH N/A
- Revenue Growth
- OKYO N/A
- TLPH N/A
- 52 Week Low
- OKYO $0.90
- TLPH $0.38
- 52 Week High
- OKYO $3.35
- TLPH $1.57
- Technical
- Relative Strength Index (RSI)
- OKYO 39.72
- TLPH 53.71
- Support Level
- OKYO $1.90
- TLPH $1.28
- Resistance Level
- OKYO $2.54
- TLPH $1.57
- Average True Range (ATR)
- OKYO 0.25
- TLPH 0.13
- MACD
- OKYO -0.06
- TLPH -0.00
- Stochastic Oscillator
- OKYO 6.83
- TLPH 54.46
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.